1. Financial Burden of Prescribed Medicines Included in Outpatient Benefits Package Schemes: Comparative Analysis of Co-Payments for Reimbursable Medicines in European Countries. (2019). Vogler, Sabine ; Pedersen, Hanne Bak ; Dedet, Guillaume.
   In: Applied Health Economics and Health Policy.
   RePEc:spr:aphecp:v:17:y:2019:i:6:d:10.1007_s40258-019-00509-z.

   Full description at Econpapers || Download paper

2. Introduction of therapeutic reference pricing in Slovenia and its economic consequences. (2018). Maretko, Nika ; Kos, Mitja.
   In: The European Journal of Health Economics.
   RePEc:spr:eujhec:v:19:y:2018:i:4:d:10.1007_s10198-017-0903-9.

   Full description at Econpapers || Download paper

3. Is the prescribing behavior of Chinese physicians driven by financial incentives?. (2014). Wang, Ying ; Dong, Weizhen ; Hao, MO ; Shen, Jay J. ; Chen, Chun ; Cochran, Christopher.
   In: Social Science & Medicine.
   RePEc:eee:socmed:v:120:y:2014:i:c:p:40-48.

   Full description at Econpapers || Download paper

4. Generic substitution policy, prices and market structure: evidence from a quasi-experiment in Finland. (2012). Linnosmaa, Ismo ; Kangasharju, Aki ; Hokkanen, Joni ; Valtonen, Hannu.
   In: Working Papers.
   RePEc:fer:wpaper:35.

   Full description at Econpapers || Download paper

5. Challenges to orphan drugs access in Eastern Europe: The case of Bulgaria. (2012). Miteva-Katrandzhieva, Tsonka ; Stefanov, Rumen ; Iskrov, Georgi.
   In: Health Policy.
   RePEc:eee:hepoli:v:108:y:2012:i:1:p:10-18.

   Full description at Econpapers || Download paper

6. Effects of Reference Pricing in Pharmaceutical Markets. (2011). Miraldo, Marisa ; Galizzi, Matteo ; Ghislandi, Simone.
   In: PharmacoEconomics.
   RePEc:spr:pharme:v:29:y:2011:i:1:p:17-33.

   Full description at Econpapers || Download paper

7. Regulatory policy and the location of bio-pharmaceutical foreign direct investment in Europe. (2011). MacGarvie, Megan ; Koenig, Pamina.
   In: Journal of Health Economics.
   RePEc:eee:jhecon:v:30:y:2011:i:5:p:950-965.

   Full description at Econpapers || Download paper

8. Regulatory policy and the location of bio-pharmaceutical FDI in Europe. (2009). MacGarvie, Megan ; Koenig, Pamina.
   In: Working Papers.
   RePEc:hal:wpaper:halshs-00566800.

   Full description at Econpapers || Download paper

9. Regulatory policy and the location of bio-pharmaceutical FDI in Europe. (2009). MacGarvie, Megan ; Koenig, Pamina.
   In: PSE Working Papers.
   RePEc:hal:psewpa:halshs-00566800.

   Full description at Econpapers || Download paper

10. Assessing the Impact of Global Price Interdependencies. (2008). Richter, Anke.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:26:y:2008:i:8:p:649-659.

    Full description at Econpapers || Download paper

1. Bruckert, E. ; Hayem, G. ; Dejager, S. ; Yau, C. ; Begaud, B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients: the PRIMO study. 2005 Cardiovascular Drugs and Therapy. 19.6 403-414
   Paper not yet in RePEc: Add citation now
   
2. Faunce, T. ; Doran, E. ; Henry, D. ; Drahos, P. ; Searles, A. ; Pekarsky, B. Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy. 2005 Globalization and Health. 1 15-
   Paper not yet in RePEc: Add citation now
   
3. Gee, M. ; Hasson, N.K. ; Hahn, T. ; Ryono, R. Effects of a tablet-splitting program in patients taking HMG-CoA reductase inhibitors: analysis of clinical effects, patient satisfaction, compliance, and cost avoidance. 2002 Journal of Managed Care Pharmacy. 8.6 453-458
   Paper not yet in RePEc: Add citation now
   

4. Ghislandi, S. ; Krulichova, I. ; Garattini, L. Pharmaceutical policy in Italy: towards a structural change?. 2005 Health Policy. 72 53-63

5. Giuliani, G. ; Selke, G. ; Garattini, L. The German experience in reference pricing. 1998 Health Policy. 44 73-85

6. Grootendorst, P. ; Stewart, D. A re-examination of the impact of reference pricing on anti-hypertensive drug plan expenditures in British Columbia. 2006 Health Economics. 15 735-742

7. Grootendorst, P.V. ; Dolovich, L.R. ; O’Brien, B.J. ; Holbrook, A.M. ; Levy, A.R. Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs. 2001 Canadian Medical Association Journal. 165 1011-1019
   Paper not yet in RePEc: Add citation now
   
8. Huber, M. ; Orosz, E. Health expenditure trends in OECD countries, 1990–2001. 2003 Health Care Financing Review. 25 1-22
   Paper not yet in RePEc: Add citation now
   
9. Kanavos, P. ; Reinhardt, U. Reference pricing for drugs: is it compatible with U.S. health care?. 2003 Health Affairs (Millwood). 22.3 16-30
   Paper not yet in RePEc: Add citation now
   
10. Kerpel-Fronius, S. Medical problems associated with the national reference pricing system in Hungary. 2004 Orvosi Hetilap. 145.17 913-918
    Paper not yet in RePEc: Add citation now
    

11. Lopez-Casanovas, G. ; Puig-Junoy, J. Review of the literature on reference pricing. 2000 Health Policy. 54 87-123

12. Maclure, M. Drug insurance utilization management policies and “reference pricing”: an illustrated commentary on the article by Vittorio Maio and colleagues. 2005 The Milbank Quarterly. 83 131-147
    Paper not yet in RePEc: Add citation now
    
13. Mantel-Teeuwisse, A.K. ; Klungel, O.H. ; Schalekamp, T. ; Verschuren, W.M.M. ; Porsius, A.J. ; de Boer, A. Suboptimal choices and dosing of statins at start of therapy. 2005 British Journal of Clinical Pharmacology. 60 83-89
    Paper not yet in RePEc: Add citation now
    
14. Marshall, J.K. ; Grootendorst, P.V. ; O’Brien, B.J. ; Holbrook, A.M. ; Levy, A.R. Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia. 2002 Canadian Medical Association Journal. 166 1655-1662
    Paper not yet in RePEc: Add citation now
    
15. Matalka, M.S. ; Ravnan, M.C. ; Deedwania, P.C. Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The alternate day versus daily dosing of atorvastatin study (ADDAS). 2002 American Heart Journal. 144 674-677
    Paper not yet in RePEc: Add citation now
    
16. McDevitt, J. ; Gurst, A. ; Chen, Y. Accuracy of tablet splitting. 1998 Pharmacotherapy. 18 193-197
    Paper not yet in RePEc: Add citation now
    

17. Puig-Junoy, J. Incentives and pharmaceutical reimbursement reforms in Spain. 2004 Health Policy. 67 149-165

18. Schneeweiss, S. ; Maclure, M. ; Soumerai, S.B. Prescription duration after drug copay changes in older people: methodological aspects. 2002 Journal of the American Geriatrics Society. 50 521-525
    Paper not yet in RePEc: Add citation now
    
19. Schneeweiss, S. ; Soumerai, S.B. ; Maclure, M. ; Dormuth, C. ; Walker, A.M. ; Glynn, R.J. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. 2003 Clinical Pharmacology and Therapeutics. 74 388-400
    Paper not yet in RePEc: Add citation now
    
20. Schneeweiss, S. ; Walker, A.M. ; Glynn, R.J. ; Maclure, M. ; Dormuth, C. ; Soumerai, S.B. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. 2002 The New England Journal of Medicine. 346 822-829
    Paper not yet in RePEc: Add citation now
    
21. Thomas, M. ; Mann, J. Increased thrombotic vascular events after change of statin. 1998 Lancet. 352 1830-1831
    Paper not yet in RePEc: Add citation now
    

1. Exploring the effectiveness of demand-side retail pharmaceutical expenditure reforms. (2023). Czypionka, Thomas ; Reiss, Miriam ; Berger, Michael ; Pock, Markus ; Rohrling, Gerald.
   In: International Journal of Health Economics and Management.
   RePEc:kap:ijhcfe:v:23:y:2023:i:1:d:10.1007_s10754-022-09337-6.

   Full description at Econpapers || Download paper

2. Exploring the effectiveness of demand-side retail pharmaceutical expenditure reforms: cross-country evidence from weighted-average least squares estimation. (2023). Czypionka, Thomas ; Reiss, Miriam ; Berger, Michael ; Pock, Markus ; Rohrling, Gerald.
   In: LSE Research Online Documents on Economics.
   RePEc:ehl:lserod:116928.

   Full description at Econpapers || Download paper

3. Attitude and Purchase Intention to Generic Drugs. (2021). da Silva, Wesley Vieira ; Arcaro, Ricardo ; da Veiga, Claudimar Pereira ; Pereira, Cassia Rita.
   In: IJERPH.
   RePEc:gam:jijerp:v:18:y:2021:i:9:p:4579-:d:543630.

   Full description at Econpapers || Download paper

4. Money back guarantee? A cost–benefit framework of performance-based agreements (PBAs) for the reimbursement of pharmaceuticals. (2019). Moramarco, Vito ; Coretti, Silvia ; Ruggeri, M ; Cicchetti, A ; Carletto, A.
   In: Eurasian Business Review.
   RePEc:spr:eurasi:v:9:y:2019:i:1:d:10.1007_s40821-018-0107-y.

   Full description at Econpapers || Download paper

5. The simultaneous effects of pharmaceutical policies from payers’ and patients’ perspectives: Italy as a case study. (2016). Armeni, Patrizio ; Otto, Monica ; Jommi, Claudio.
   In: The European Journal of Health Economics.
   RePEc:spr:eujhec:v:17:y:2016:i:8:d:10.1007_s10198-015-0739-0.

   Full description at Econpapers || Download paper

6. Corruption and health expenditure in Italian Regions. (2014). Lagravinese, Raffaele ; Paradiso, Massimo.
   In: Economics Bulletin.
   RePEc:ebl:ecbull:eb-14-00070.

   Full description at Econpapers || Download paper

7. The impact of generic reference pricing in Italy, a decade on. (2013). Ghislandi, Simone ; Armeni, Patrizio ; Jommi, Claudio.
   In: The European Journal of Health Economics.
   RePEc:spr:eujhec:v:14:y:2013:i:6:p:959-969.

   Full description at Econpapers || Download paper

8. Corruption and health expenditure in Italy. (2012). Lagravinese, Raffaele ; Paradiso, Massimo.
   In: MPRA Paper.
   RePEc:pra:mprapa:43215.

   Full description at Econpapers || Download paper

9. Effects of Reference Pricing in Pharmaceutical Markets. (2011). Miraldo, Marisa ; Galizzi, Matteo ; Ghislandi, Simone.
   In: PharmacoEconomics.
   RePEc:spr:pharme:v:29:y:2011:i:1:p:17-33.

   Full description at Econpapers || Download paper

10. Does the Market Share of Generic Medicines Influence the Price Level?. (2011). Simoens, Steven ; Dylst, Pieter.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:29:y:2011:i:10:p:875-882.

    Full description at Econpapers || Download paper

11. Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-Driven Markets. (2011). Danzon, Patricia ; Furukawa, Michael F..
    In: NBER Working Papers.
    RePEc:nbr:nberwo:17226.

    Full description at Econpapers || Download paper

12. The impotence of price controls: Failed attempts to constrain pharmaceutical expenditures in Greece. (2011). O'Donnell, Owen ; Lambrelli, Dimitra .
    In: Health Policy.
    RePEc:eee:hepoli:v:101:y:2011:i:2:p:162-171.

    Full description at Econpapers || Download paper

13. The impact of generic substitution on the turnover and gross margin of pharmaceutical companies a survey 1 year and 5 years after the introduction of generic substitution in Finland. (2009). Ahonen, Riitta ; Karttunen, Pekka ; Bengtstrom, Marina ; Timonen, Johanna.
    In: Health Policy.
    RePEc:eee:hepoli:v:92:y:2009:i:2-3:p:116-123.

    Full description at Econpapers || Download paper

14. Pharmaceutical pricing and reimbursement reforms in Greece. (2008). Yfantopoulos, John.
    In: The European Journal of Health Economics.
    RePEc:spr:eujhec:v:9:y:2008:i:1:p:87-97.

    Full description at Econpapers || Download paper

15. Il prezzo di riferimento nel quadro regolatorio del mercato farmaceutico. (2007). SALERNO, Nicola ; Riccaboni, Massimo ; Pammolli, Fabio ; Magazzini, Laura ; Bonassi, Chiara.
    In: Working Papers CERM.
    RePEc:ern:wpaper:04-2007.

    Full description at Econpapers || Download paper

16. Effects of essential medicines on cardiovascular products available for the market in Thailand. (2007). Charumanee, Suporn ; Burapadaja, Siriporn ; Kawasaki, Naohito ; Ogata, Fumihiko.
    In: Health Policy.
    RePEc:eee:hepoli:v:84:y:2007:i:1:p:67-74.

    Full description at Econpapers || Download paper

17. Pricing and reimbursement of in-patent drugs in seven European countries: A comparative analysis. (2007). De Compadri, Paola ; Garattini, Livio ; Cornago, Dante .
    In: Health Policy.
    RePEc:eee:hepoli:v:82:y:2007:i:3:p:330-339.

    Full description at Econpapers || Download paper

18. Impact of a generic substitution reform on patients and societys expenditure for pharmaceuticals. (2007). Petzold, Max G. ; Andersson, Karolina ; Bergstrom, Gina ; Carlsten, Anders.
    In: Health Policy.
    RePEc:eee:hepoli:v:81:y:2007:i:2-3:p:376-384.

    Full description at Econpapers || Download paper

19. Does therapeutic reference pricing always result in cost-containment?: The Hungarian evidence. (2007). Kalo, Zoltan ; Muszbek, Noemi ; Bidlo, Judit ; Bodrogi, Jozsef.
    In: Health Policy.
    RePEc:eee:hepoli:v:80:y:2007:i:3:p:402-412.

    Full description at Econpapers || Download paper

20. Pharmaceutical policy in Italy. (2006). Garattini, Livio ; Cornago, Dante .
    In: The European Journal of Health Economics.
    RePEc:spr:eujhec:v:7:y:2006:i:2:p:89-90.

    Full description at Econpapers || Download paper

21. The Italian health‐care system. (2005). France, George ; Taroni, Francesco ; Donatini, Andrea .
    In: Health Economics.
    RePEc:wly:hlthec:v:14:y:2005:i:s1:p:s187-s202.

    Full description at Econpapers || Download paper

Report date: 2025-10-03 23:34:11 || Missing content? Let us know